Meeting Coverage
Presentation Format at a Glance at ESC 2021
Download ESC Congress 2021 Program (PDF)
Read MoreIt’s Time! ESC Congress 2021 is Here
Anticipation is rising for the European Society’s Annual Congress, an event like no other, providing access to ground-breaking science, essential clinical updates and the chance to interact with a renowned international...
Read More
Conference Highlights: IAS 2021
New research was presented at IAS 2021, the virtual 11th International AIDS Society Conference on...
Read More
Highlights from ASCO 2021: Leukemia – eBook
ASCO Leukemia Annual Meetingv3 Featuring… ELEVATE-RR: Acalabrutinib demonstrates similar...
Read MoreEarly-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab with Stereotactic Body Radiotherapy
A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...
Read MoreT-DXd Combinations in HER2-positive Metastatic Breast Cancer
The DESTINY-Breast07 trial will test trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer, as a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion...
Read MoreELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety compared with ibrutinib
The phase 3 ELEVATE-RR trial was a head-to-head comparison of acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukemia. The first results of this study demonstrated that acalabrutinib had...
Read MoreELEVATE-TN: long-term efficacy in chronic lymphocytic leukemia
Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in patients with chronic lymphocytic leukaemia (CLL). Results from the 4-year follow-up of the ELEVATE-TN study...
Read MoreDurvalumab after chemoradiation proven safe in elderly NSCLC patients
The addition of durvalumab after chemoradiation (CRT) in unresectable stage 3 non-small cell lung cancer (NSCLC) can be safely delivered in elderly patients ≥70 years with comparable improvement in overall survival (OS), as...
Read MoreDoubling overall survival in US veterans with stage 3 non-small cell lung cancer
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Read MorePreventing interstitial lung disease in patients on trastuzumab detruxtecan
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable...
Read MoreT-DXd Response on Brain Mets HER2+ Breast Cancer
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...
Read More5-year PACIFIC data hold strong in NSCLC
Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...
Read More
The EFFORT needed to overcome PARP resistance in ovarian cancer
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity...
Read MoreIncorporating New Targeted Therapies for Indolent B-Cell Lymphomas
For a presentation at ASCO 2021, John Seymour, PhD, Professor at the Peter MacCallum Cancer Centre of the Royal Melbourne Hospital and University of Melbourne in Australia, discussed six FDA-approved agents or drug...
Read More